Pfiz­er culls RSV treat­ment from Re­Vi­ral ac­qui­si­tion

Pfiz­er has ter­mi­nat­ed de­vel­op­ment of its RSV treat­ment can­di­date sisuna­tovir, a vi­ral in­hibitor picked up in its up to $525 mil­lion ac­qui­si­tion of Re­Vi­ral in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER